
	Mr. Richard I. Steinhart served as the Chief Financial Officer, Vice President for Finance and Treasurer of MELA Sciences, Inc. since April 24, 2006 until December 2013. Mr. Steinhart has been the Secretary of Electro-optical Sciences since November 2006 and serves as its Principal Accounting Officer. He is a General Partner of Healthcare Platform Partners I, L.P. and SAE Ventures. He joined EOS from Forest Street Capital, where he served since 1992 as Managing Director of this boutique investment firm focused on healthcare and technology companies. During his tenure, he founded several medical technology and biopharmaceutical companies, and structured and negotiated equity investments for numerous public and private companies. From May 1991 to May 1992, he served as Chief Financial Officer and Vice President of Emisphere Technologies Inc. From 1985 to 1991, he was the General Partner and served as the Chief Financial Officer of CW Group Inc. He began his career at Price Waterhouse (now PricewaterhouseCoopers). He served as an Executive Officer of PricewaterhouseCoopers, LLP. He has been an Independent Director of Actinium Pharmaceuticals, Inc. since November 12, 2013. He serves on the Board of Directors of several medical technology and biotechnology companies. He served as a Director of Manhattan Pharmaceuticals, Inc. (now TG Therapeutics, Inc.) from July 2004 to December 29, 2011. He served as a Director of a number of privately-held companies, including ARRIS Pharmaceuticals, Inc., Membrex, Inc., and Photest, Inc. He is a Certified Public Accountant (AICPA). He holds a Bachelors of Business Administration and Masters of Business Administration from Pace University.
